https://www.tonixpharma.com/news/presentation/daugherty-cicon-2023/
CICON: mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated...
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders,...
ciconmsamtnxsuppressestumor